-
Mashup Score: 13Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas - 1 month(s) ago
The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the …
Source: pmc.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma - 1 month(s) ago
The safety, tolerability, efficacy, and pharmacokinetics of tirabrutinib, a second-generation, highly selective oral Bruton’s tyrosine kinase inhibitor, were evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL). Patients …
Source: pmc.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
@Eddie_Cliff CSF/plasma ratio of tira approaches 18%, higher than that of ibrutinib at 7%: https://t.co/aLrMYeFAfq Also tira with more selective binding to BTK as well as upstream FYN/LYNa, also less off-target kinase activity (less toxicity?): https://t.co/uT3z4mCXSz https://t.co/K1ZYdo2y6W
-
-
Mashup Score: 1
Program: Oral and Poster Abstracts Type: Oral Session: 626. Aggressive Lymphomas: Clinical and Epidemiological: Challenging Subtypes of Aggressive Lymphomas Hematology Disease Topics & Pathways: Research, Epidemiology, Lymphomas, Clinical Research, B Cell lymphoma, Diseases, Real-world evidence, Aggressive lymphoma, Lymphoid Malignancies Juan Pablo Alderuccio, MD 1, Jahanzaib Khwaja 2, Sunwoo Han, PhD 3 *, Paola Ghione, MD, MSEpi 4, Imran A. Nizamuddin, MD 5, Aditi Saha, MBBS 6, Ning Dong, MD 7, Yucai
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
@JuanAlderuccio @CwynKate Much more detail about clinical & treatment characteristics in the de novo and R/R cohorts in the abstract text: https://t.co/BqyoBM6Rbf #ASH24 #lymsm
-
-
Mashup Score: 21Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma - 1 month(s) ago
Ollila et al address a challenging problem: can the risk for central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma be predict
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
MYD88/CD79B mut by PCR➡️CNS relapse #ASH24: - 270 pts, 20% MYD88 and/or CD79Bmut - mut cohort: 3- and 8-yr CNS relapse rates 11% & 25% (!!!) - CNS-IPI high-risk: 22% mut pts had relapse vs 16% non-mut Previously seen in Ollila 2021 Blood paper: https://t.co/PI1TDiyLJZ #lymsm https://t.co/gEyqx1HfA2
-
-
Mashup Score: 6Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study - 2 month(s) ago
Key Points. One year fixed-duration Ven-Obi produces durable treatment-free remissions, with a 6-year PFS rate of 53% and TTNT rate of 65%, in CLLEnd-of-tr
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
PROs 6-yr f/u CLL14 @Othman_Al_Sawaf: - KM-type time until definitive deterioration (TUDD) of QLQ-C30 - significantly longer TUDD in VO arm for global QOL and fatigue - however, both arms with similar improvement over time in these domains #lymsm 1/x https://t.co/GzRDuyO10e https://t.co/Oz4nXvVdJK
-
-
Mashup Score: 7
What does it mean to be the perfect doctor? Are you a medical student hoping to be one, a patient who wants to have one, or someone curious about the human side of medicine? This collection of stories offers a glimpse into the diverse lives of doctors and illustrates that there are as many versions of perfect as there are people. The students, doctors, and patients in this book learn what the perfect doctor means to them through loss, humor, and reflection. Their elaborative, insightful, sometimes funny, and always heartfelt narratives can help you decide what the perfect doctor means to you.
Source: www.lulu.comCategories: General Medicine News, Hem/OncsTweet-
@Aleena_Paul @InTrainingDoc @inHouseMag @MosaicinMed @InterveneStream @GoldFdtn @riagpal @MonishaVasa @OMETinyHeartsMD Finally, our latest book, curated by neurocritical care physician Dr. @sashkind, queries the imperfect pursuit of the 'perfect doctor' ideal through 40 essays by patients, trainees and physicians. #medhum https://t.co/HmyDeMpo0k https://t.co/kzpDAIokgn
-
-
Mashup Score: 7in-Training: 2020 In Our Words - 2 month(s) ago
Peer-edited narratives written by medical students about their experiences throughout the year 2020
Source: www.lulu.comCategories: General Medicine News, Hem/OncsTweet-
@Aleena_Paul @InTrainingDoc @inHouseMag @MosaicinMed @InterveneStream @GoldFdtn @riagpal @MonishaVasa Our sixth book, curated by @InTrainingDoc editors-in-chief Pallavi & Sam, compiles narratives from medical students who lived through the pandemic year of 2020, with themes of resilience, advocacy, and the fundamental changes to #meded. #medtwitter #medhum https://t.co/ZUSbxHBp23 https://t.co/QcjaXosIhF
-
-
Mashup Score: 6Girl In A Bowtie: Lessons of a Pediatric Resident - 2 month(s) ago
Join resident physician Dr. Ogie M. Ezeoke, the Girl In A Bowtie, in her adventures in the big hospital by the sea. From pages to potassium to the angry airway, each chapter is a lesson in the art of medicine and the wonder of pediatrics.
Source: www.lulu.comCategories: General Medicine News, Hem/OncsTweet-
@Aleena_Paul @InTrainingDoc @inHouseMag @MosaicinMed @InterveneStream @GoldFdtn @riagpal @MonishaVasa Written by pediatrics resident Dr. Ogie M. Ezeoke (@OMETinyHeartsMD), our seventh book is a love letter to training as a pediatrician, told through narrative stories about experiences in the 'big hospital by the sea.' #pediatrics #narrativemed #medhum https://t.co/cMRZf6gQ4j https://t.co/wwpsSafy10
-
-
Mashup Score: 9International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma | Journal of Clinical Oncology - 2 month(s) ago
PURPOSENodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and immunoarchitectural patterns (IAPs) for all stages of …Our lymphocyte-predominant IPS identifies most patients as low-risk regardless of pathologic patterns.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Nordic NLPHL experience @glimelius #ISHL13: - 752 pts, f/u 8-10 yrs - 19% of cohort relapsed at median 2.9-4.5 yrs - 4% transformation rate - most got RT alone Great comparison with @glow_nlphl study: https://t.co/OAh6OhTVXg #lymsm https://t.co/p1yNHXwnFU
-
-
Mashup Score: 12
Cancer management in older frail patients can be complex, given the high decline in functional status, comorbidity, and limited life expectancy affecting this group of patients. Therefore, this study aimed to investigate whether oncological treatment combined with comprehensive geriatric assessment (CGA) and tailored follow-up interventions improved or maintained quality of life (QoL) in older prefrail and frail patients with cancer.
Source: www.geriatriconcology.netCategories: General Medicine News, Hem/OncsTweet-
RCT specialized geriatric f/u (vs PCP f/u) in frail/prefrail solid tumor pts: - 363 pts, 58% frail, 55% M1 - no difference in any QOL or PROs between arms Important negative study; different interventions may be needed for specific malignancies. #gerionc https://t.co/A8GA5E1IhH
-
Parsaclisib (PI3Ki)+chemo 1L LBCL @YucaiWangMD #ASH24: - 50 pts (7 pola-R-CHP) - RCHOP: ORR 98%, CR 91%, 2-yr PFS 85%, OS 95% - Pola: ORR 100%, CR 100%, 1 relapse, all alive Plans for RCT? Love to see PI3K/Akt/mTOR back in action (see our trial): https://t.co/4f8xc6ygYa #lymsm https://t.co/u4Jj3Arv3P